Oxford Biodyn Regulatory News (OBD)

20 April 2017

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Dr Claudio Carini joins the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Steering Committees

OBD representation on prestigious U.S. biomarker committees

Oxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, announces that Oxford BioDynamics and Dr Claudio Carini, a member of Oxford BioDynamics' Scientific Advisory Panel, have been invited to join the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees.

The Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that endeavours to discover, develop, and seek regulatory approval for biological markers, known as biomarkers, to support new drug development, precision medicine, and medical diagnostics.

The Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organisations.

Dr Carini has prior experience as a member of the FNIH Biomarkers Consortium Steering Committees, as well as having consulted and sat on many other distinguished international advisory boards and committees including: the Medical Research Council (UK), Innovative Medicine Initiative (IMI-EU) and the PML Consortium.

Christian Hoyer Millar, CEO of Oxford BioDynamics, commented:

"We are delighted that Claudio will be joining these prestigious biomarker committees. The FNIH Biomarkers Consortium aims to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease, and this is a goal that is shared by Oxford BioDynamics.

"We believe that becoming a member of these important FNIH committees will be beneficial as we continue to progress towards our strategic aim of becoming the industry standard for epigenetic biomarker discovery."

For further details contact:

Oxford BioDynamics Plc +44 (0)1865 518910

Christian Hoyer Millar, CEO

Katie Long, CFO

FTI Consulting +44 (0)20 3727 1000

Financial Public Relations Advisor

Julia Phillips

Brett Pollard

Natalie Garland-Collins

Matthew Moss

Stifel Nicolaus Europe Limited +44 (0)20 7710 7600

Nominated Advisor and Broker

David Arch

Jonathan Senior

Peter Lees

Ben Maddison

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.